We're sorry, but we're unable to process your login. Please try again.
We're sorry, you are not authorized to access this site. Please contact your local Merck representative if you have any inquiries.
This page requires you to register for an account with Merck. Please login with your Merck account credentials below, or register for a new account.

Log in with Merck
{* #signInForm *}
{* signInEmailAddress *}
{* currentPassword *}
{* captcha *}
{* /signInForm *}

1. The review process

 

The Scientific Steering Committee for the innovation grant is comprised of Beverly MK Biller, John Kopchick, Xiaoping Luo, Veronica Mericq, Martin Savage and Christian Strasburger. The Committee oversees a rigorous process of peer review and assessment of eligible projects, before validating its selection of grant awardees.

The names of the applicants and their institutions are completely blinded to the members of the committee to keep the scientific merit of the proposals as the key criteria for selection. All proposals are rated from 1 to 5 (with 5 being the highest) against each of the following criteria:

  • Innovation
  • Scientific rationale
  • Clarity
  • Feasibility
  • Impact of research.

A final score is then calculated and the projects ranked accordingly. After each round of selection, the GGI secretariat, on behalf of EMD Serono* will contact successful applicants individually to inform them of the status of their application, and if necessary, request additional information.

All projects that pass to the second round of review will have to submit the formal protocol, the budget and a signed document that confirms their acceptance of the grant rules and regulations for advanced applications. Based on this information, the Scientific Steering Committee will make their final acceptance decisions.

 

2. How is the awarding of the grant formalised?

 

The grant recipient will enter into a written agreement with EMD Serono*, which documents the conditions of the grant and the further collaboration between EMD Serono* and the awardee(s).

 

3. What about publicity?

 

EMD Serono* retains the exclusive right to issue any press release or any kind of public communication about the Grant for Growth Innovation, the grant(s) and the awardee(s).

 

4. What happens to applications that are not successful?

 

EMD Serono* treats all submissions confidentially and information relating to submissions that are not selected for a grant is kept confidential.

 

5. Data protection information

 

By submitting the information requested in the letter of intent you understand and agree that EMD Serono* may share personally identifiable data about you with outside companies or agents working on our behalf, as well as company's subsidiaries and affiliates, to help process the submissions. The importance of security for all personally-identifiable information associated with visitors to the web site is of utmost concern to us. Unfortunately, no data transmission over the internet can be guaranteed to be secure. As a result, EMD Serono* cannot ensure or warrant the security of any information you transmit to us, and you do so at your own risk. Once we receive your personally-identifiable information, we will take reasonable efforts to ensure its security on our systems.

 

*The biopharma business of Merck KGaA, Darmstadt, Germany

Leaving website.

You are leaving our website. This link will take you to a website to which our Privacy Policy and Conditions may not apply. Merck has no control over the contents and policies of third party sites or resources, and accepts no responsibility for them or for any loss or damage that may arise from your use of them. Please check Privacy Policy and Conditions of the linked website.